{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.5","upperLimit":"12.5","value":"7.8"},{"groupId":"OG001","lowerLimit":"3.6","upperLimit":"14.9","value":"6.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"10"}],"units":"Participants"}],"dispersionType":"95% Confidence Interval","groups":[{"description":"Vandetanib 300 mg/day oral","id":"OG000","title":"Vandetanib"},{"description":"Vinorelbine 30 mg/m2 iv, administrated weekly","id":"OG001","title":"Vinorelbine"}],"paramType":"MEDIAN","populationDescription":"Only patients in the evaluable for efficacy population were included. It was defined as all treated patients with no major deviations from the eligibility criteria affecting the evaluation of efficacy, who completed at least 2 cycles (unless progressive disease occurred at cycle 1) and who had at least one post-treatment tumour assessment.","reportingStatus":"POSTED","timeFrame":"Assessed from baseline to 12 months.","title":"Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"Months"}